Detalles de la búsqueda
1.
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
N Engl J Med
; 386(10): 942-950, 2022 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35263519
2.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 382(6): 514-524, 2020 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31826360
3.
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.
Breast Cancer Res Treat
; 195(1): 55-64, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35829935
4.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
N Engl J Med
; 375(18): 1738-1748, 2016 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27717303
5.
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
Breast Cancer Res Treat
; 168(1): 127-134, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29164421
6.
Second cancers in Hodgkin's lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients.
Int J Clin Pract
; : e13235, 2018 Jul 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-30011112
7.
[Cardiovascular complications of cancers and anti-cancer therapy]. / Kardiovaskulární komplikace nádoru a jejich lécby.
Vnitr Lek
; 63(3): 200-209, 2017.
Artículo
en Cs
| MEDLINE | ID: mdl-28379023
8.
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 17(6): 811-821, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27155741
9.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 17(3): 367-377, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26874901
10.
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Cancer
; 119(10): 1908-15, 2013 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23504821
11.
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
J Clin Oncol
; 41(24): 4014-4024, 2023 08 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37348019
12.
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Eur J Cancer
; 184: 48-59, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898233
13.
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
J Clin Oncol
; 41(2): 198-205, 2023 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36332179
14.
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Lancet
; 377(9769): 914-23, 2011 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-21376385
15.
First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study.
Oncology
; 82(4): 218-27, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22508241
16.
Biomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy.
Diagnostics (Basel)
; 12(7)2022 Jul 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35885644
17.
Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.
Cancers (Basel)
; 14(7)2022 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35406370
18.
Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.
Onkologie
; 34(5): 233-8, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21577028
19.
Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.
Cancers (Basel)
; 13(7)2021 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-33808149
20.
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
Clin Breast Cancer
; 21(3): 181-190.e2, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33148479